China's Brain-Computer Interface Market Accelerates with $165M Fund, Insurance Integration

China's brain-computer interface industry is advancing rapidly from research to commercialization, backed by strong policy support, expanding clinical trials, and growing investor interest. Provinces such as Sichuan, Hubei, and Zhejiang have already set medical service pricing for BCI, speeding its inclusion in the national medical insurance system.

In August 2025, China's industry ministry and six other agencies released a national roadmap to further speed development of BCIs. The plan targets major technical milestones by 2027, common industry standards, and a full supply chain by 2030, with the goal of building globally competitive BCI companies and supporting smaller specialized firms. In December, at the 2025 Shenzhen BCI & Human-Computer Interaction Expo, China announced an 11.6 billion yuan ($165 million) brain science fund to support BCI companies from research through commercialization.

Over the next three to five years, BCI use is likely to stay concentrated in healthcare, with the market reaching multibillion-dollar scale as insurance coverage expands. China's BCI market was expected to grow to more than $530 million (3.8 billion yuan) in 2025, up from 3.2 billion yuan in 2024, with projections putting the market at over 120 billion yuan by 2040.

China's national health insurance means quicker commercialization once the state approves a device. This compares to the U.S. where even after the FDA approves a device, private insurers, as the main payers, must each individually do so. Researchers have completed the country's first fully implanted, wireless BCI trial — only the second globally — allowing a paralyzed patient to control devices without external hardware.

In traditional electrical BCIs, Chinese firms have achieved clinical progress in motor and language decoding, spinal cord reconstruction, and stroke rehabilitation, with over 50 flexible implantable BCI clinical trials completed by mid-2025. Next-generation efforts are now moving toward whole-brain neural decoding and encoding, including ultrasound-based approaches.

China's rapid progress in BCI comes down to four factors: strong policy support with cross-department collaboration that aligns technical standards and medical reimbursement; vast clinical resources, including large patient pools and lower research costs that accelerate trials; mature industrial manufacturing spanning semiconductors, AI, and medical hardware, which supports fast R&D and prototyping; and strategic investment with both state-led funds and private capital surging under national initiatives.

Recent key deals include Shanghai-based BCI startup StairMed Technology raising $48 million (350 million yuan) in Series B funding in February 2025. BrainCo, a neurotech company developing its noninvasive BCIs and bionic limbs, has also quietly filed for a Hong Kong IPO after raising $287 million (2 billion yuan) earlier this year. Gestala, which launched in January, is in talks with investors to close an angel round soon.

China's BCI startups are ramping up to challenge U.S. leaders like Neuralink, Synchron, and Paradromics. Among the most active players in China are NeuroXess, Neuracle, NeuralMatrix, BrainCo, Bo Rui Kang Tech, Aoyi Tech, Brainland Tech, and Zhiran Medical. They span approaches from implantable flexible interfaces to noninvasive brain-computer technologies.

BCIs are taking two paths. The first is invasive electrophysiological BCIs like NeuroXess and Neuralink that implant electrodes in people's brains for precise neuron-level signals. The second type is noninvasive approaches.